Duncan K
GlaxoSmithKline, Gunnels Wood Road, Stevenage SG1 2NY, UK.
Curr Pharm Des. 2004;10(26):3185-94. doi: 10.2174/1381612043383223.
There is an urgent need for new antimycobacterial drugs, and in particular for novel agents that will shorten the duration of tuberculosis chemotherapy, or overcome drug-resistant strains of the causative organism, Mycobacterium tuberculosis. Our knowledge of the tubercle bacillus and its complex interaction with the human host has improved dramatically in recent years, particularly with the determination of its complete genome sequence. New genome-scale tools are being applied to aid in drug target identification, alongside traditional approaches aimed at understanding the basic biology of M. tuberculosis. Many potential drug targets have been identified, but very few have been validated by showing that they are essential for growth or survival of the bacterium. In this review, the landscape of potential drug targets is surveyed.Structural Bioinformatic Approaches to the Discovery of New Antimycobacterial Drugs.
迫切需要新型抗分枝杆菌药物，尤其是能够缩短结核病化疗疗程或克服致病病原体结核分枝杆菌耐药菌株的新型药物。近年来，我们对结核杆菌及其与人类宿主复杂相互作用的认识有了显著提高，特别是在确定其完整基因组序列方面。新的基因组规模工具正在被应用于辅助药物靶点的识别，同时还有旨在了解结核分枝杆菌基本生物学特性的传统方法。已经确定了许多潜在的药物靶点，但通过证明它们对细菌的生长或存活至关重要而得到验证的却很少。在这篇综述中，对潜在药物靶点的情况进行了调查。发现新型抗分枝杆菌药物的结构生物信息学方法。
